Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HDAC/HMA combo shows ‘remarkable’ activity in PTCL

Key clinical point: Romidepsin and 5-azacytadine showed good activity in peripheral T-cell lymphomas (PTCL).

Major finding: In total, 11 of 16 patients with angioimmunoblastic T-cell lymphoma (AITL) or primary cutaneous follicular helper T-cell lymphoma (PTCL-TFH) had a clinical response.

Study details: A phase 2 open-label trial of 25 patients with PTCL.

Disclosures: Dr. Falchi reported having no financial disclosures. Other investigators reported funding from Celgene, which supported the study.

Citation:

Falchi L et al. 15-ICML, Abstract 129.